Research Highlight
GlycoNet researchers develop new chemical biological tools to monitor Parkinson’s disease
Researchers are a step closer to understanding how Parkinson’s disease develops and progresses.
GlycoNet startup, ABOzymes, completes seed financing round to fund development of technology to enable universal organ transplants and blood transfusions
Glycomics is an integral part of ABOzymes’ life-saving research and technology development.
Engagement and collaboration in action at the 2022 Canadian Glycomics Symposium
Read some highlights from the 2022 Canadian Glycomics Symposium.
More stories
- All
- Awards
- Community
- Network Profile
- Press Release
- Research Highlight
Enzymes linked with immune cell activity could hold key to better understanding inflammation
Findings show promise for developing potential new anti-inflammatory drugs and treatments for autoimmune diseases.
GlycoNet partner company, Alectos Therapeutics, enters ground-breaking $700 million agreement with Biogen
This collaboration combines Alectos’ expertise in small-molecule therapeutics with Biogen’s development capabilities in movement disorders.
Glycomics is writing the next chapter in bioinnovation
In BIOTECanada’s Insights Magazine, GlycoNet Scientific Director Warren Wakarchuk writes about the importance of glycomics, opportunities to leverage glycomics, and Canadian glycomics expertise.
GlycoNet and partners invest $7.7 million in Canadian health innovation
This investment will support state-of-the-art health research for Canada’s leading diseases, including cancer, diabetes, dementia, muscular dystrophy and universal donor blood.
Molecules with anti-inflammatory, restorative properties could be key to tackling neurodegenerative disease
GlycoNet researchers are studying a group of molecules that could provide insight into treating and monitoring neurodegenerative diseases.
GlycoNet researcher receives Scientific Achievement and Innovation Award
Dr. Ratmir Derda’s achievements were recently recognized with an award at BioAlberta’s 2021 Awards Gala.
GlycoNet investigator presents game-changing glycomics research to the Parliamentary Health Research Caucus
Dr. Lori Burrows shared how glycomics research is being used to develop a more effective vaccine against turberculosis.
New research reveals clues to how antibodies get fine-tuned to fight infection
Scientists discover a cellular mechanism that may yield insights into improving vaccines and better understanding cancer and autoimmune diseases.
New educational resources bolster vaccine confidence, information literacy
GlycoNet received a NSERC PromoScience grant and partnered with the Centre for Mathematics, Science and Technology Education to develop resources that educators can use to teach the science behind vaccines and engage students in critical thinking.
Canadian Glycomics Network
E5-33 Gunning/Lemieux Chemistry Centre
University of Alberta, T6G 2G2
Tel: 780-492-6204
Fax: 780-492-4147
Subscribe to GlycoNet’s Newsletter
© CANADIAN GLYCOMICS NETWORK (GLYCONET). ALL RIGHTS RESERVED.
English 
French